{"id":"NCT01181167","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","officialTitle":"A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-01","completion":"2010-03","firstPosted":"2010-08-13","resultsPosted":"2015-01-26","lastUpdate":"2019-03-05"},"enrollment":610,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Prevention","Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"edoxaban","otherNames":[]},{"type":"DRUG","name":"enoxaparin sodium","otherNames":[]}],"arms":[{"label":"DU-176b","type":"EXPERIMENTAL"},{"label":"enoxaparin sodium","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.","primaryOutcome":{"measure":"Incidence of Subjects With Venous Thromboembolism Events","timeFrame":"2 weeks","effectByArm":[{"arm":"DU-176b","deltaMin":2.4,"sd":null},{"arm":"Enoxaparin Sodium","deltaMin":6.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":["27980462"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":303},"commonTop":["Alanine aminotransferase increased","Gamma-glutamyltransferase increased","Aspartate aminotransferase increased","Blood urine present","Blood alkaline phosphatase increased"]}}